Life Science Investing Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases 2025 Annual Meeting
Life Science Investing Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Life Science Investing Galectin Therapeutics to Present at the American Association for the Study of Liver Disease Liver Meeting 2025
Life Science Investing Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Galectin Therapeutics Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA
pharmaceutical investing Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
pharmaceutical investing Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
Allied Critical Metals Confirms Ultra High-Grade Tungsten Zone at Borralha with 18.0 m @ 0.85 % WO3 including 4.0 m @ 3.72 % WO3
Pinnacle Identifies Gold-Silver Mineralization at Historic La Dura Mine, Extending Mineralized Horizon to Almost 500 Metres
